Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
April 16, 2019 16:05 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present at the Needham & Company 18th Annual Healthcare Conference April 9, 2019
April 02, 2019 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team
March 29, 2019 08:00 ET
|
Selecta Biosciences, Inc.
-First patient enrolled in COMPARE trial evaluating efficacy and safety of SEL-212 v. KRYSTEXXA® in patients with chronic refractory gout-Strengthened management and clinical teams with the...
Selecta Biosciences Announces New Employment Inducement Grant
March 26, 2019 16:05 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
Selecta Biosciences Announces Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update
March 15, 2019 08:00 ET
|
Selecta Biosciences, Inc.
Phase 2 head-to-head (COMPARE) clinical trial of SEL-212 vs. KRYSTEXXA® to begin in 1Q19, interim six-month data expected in 4Q19Collaboration with CureCN projected to dose first patient with...
Selecta Biosciences to Report Fourth Quarter and Year End 2018 Financial Results and Provide Corporate Update
March 08, 2019 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
Selecta Biosciences to Present at the Cowen Annual Health Care Conference March 13, 2019
March 06, 2019 16:01 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
Selecta Biosciences Announces Pricing of Public Offering of Common Stock
January 23, 2019 09:19 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
Selecta Biosciences Announces Proposed Public Offering of Common Stock
January 22, 2019 16:01 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
Selecta Biosciences Expands Potential for ImmTOR™ Platform and Streamlined Structure Under Leadership of New CEO, Carsten Brunn, Ph.D.
January 03, 2019 16:11 ET
|
Selecta Biosciences, Inc.
Reported completion of SEL-212 Phase 2 study with positive efficacy and tolerability results observed in the clinical trial, in addition to monthly dosing, indicating potential to serve unmet need for...